Abivax (ABVX) Operating Income (2022 - 2026)

Abivax's Operating Income history runs 5 years deep, the most recent figure standing at -$65.8 million for Q1 2026.

• In Q1 2026, Operating Income fell 32.59% year-over-year to -$65.8 million; the TTM figure through Mar 2026 stood at -$296.3 million (down 57.12% YoY), while the FY2025 annual figure was -$286.5 million, down 54.96% from the prior year.
• Operating Income for Q1 2026 stood at -$65.8 million, up from -$83.5 million in the prior quarter.
• The five-year high for Operating Income was -$38.0 million in Q2 2024, with the low at -$137.1 million in Q4 2023.
• The 5-year median for Operating Income is -$55.1 million (2024), against an average of -$67.0 million.
• The sharpest annual moves came in 2023 and 2024: Operating Income sank 107.34% in 2023, then soared 66.62% in 2024.
• Abivax's Operating Income stood at -$66.1 million in 2022, then plunged by 107.34% to -$137.1 million in 2023, then jumped by 66.62% to -$45.8 million in 2024, then plunged by 82.41% to -$83.5 million in 2025, then advanced by 21.12% to -$65.8 million in 2026.
• Business Quant data shows ABVX's Operating Income at -$65.8 million in Q1 2026, -$83.5 million in Q4 2025, and -$94.4 million in Q3 2025.